Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib.
作者： Yi Ling Teo , Xiu Ping Chue , Noan Minh Chau , Min-Han Tan , Ravindran Kanesvaran
DOI: 10.1007/S11523-014-0349-2
关键词:
摘要: An attenuated dosing (AD) regimen of 37.5 mg daily in repeated 4 week on, 2 off cycles has been proposed to ameliorate frequent dose modifications caused by the toxicity observed with approved sunitinib for metastatic renal cell carcinoma (mRCC). This study aimed determine effect drug exposure on and clinical response patients receiving this regimen. All mRCC AD were invited participate. In each cycle, plasma levels assessed. Clinical responses assessed after two cycles. A total 36 recruited. Patients who manifested ≥grade mucositis (126.46 vs 84.81 ng/mL, p = 0.04) altered taste (159.91 105.22 0.05) had higher than those grade 1 or no toxicity. Twenty-six completed treatment cycles; four (15 %) partial responses, 15 (58 a stable disease 7 (27 progressive disease. No difference was found among different outcomes. The Asian provided sufficient lower incidence toxicity, being experienced
springer.com
sci-hub.se 参考文章(23)
Se‐Hoon Lee, Yung‐Jue Bang, Paul Mainwaring, Christina Ng, John W‐C Chang, Philip Kwong, Rubi K Li, Virote Sriuranpong, Chee‐Keong Toh, Jinyu Yuan, Susan Pitman Lowenthal, Hyun C Chung, None, Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy Asia-pacific Journal of Clinical Oncology. ,vol. 10, pp. 237- 245 ,(2014) , 10.1111/AJCO.12163
Lesley J. Murray, Tinya J. Abrams, Kelly R. Long, Theresa J. Ngai, Lisa M. Olson, Weiru Hong, Paul K. Keast, Jacqueline A. Brassard, Anne Marie O'Farrell, Julie M. Cherrington, Nancy K. Pryer, SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clinical & Experimental Metastasis. ,vol. 20, pp. 757- 766 ,(2003) , 10.1023/B:CLIN.0000006873.65590.68
A PARKINSON, The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicology and Applied Pharmacology. ,vol. 199, pp. 193- 209 ,(2004) , 10.1016/J.TAAP.2004.01.010
Hui Shan Tan, Huihua Li, Yu Wen Hong, Chee-Keong Toh, Alvin Wong, Gilberto Lopes, Miah Hiang Tay, Alexandre Chan, Xin Yao, Tiffany Tang, Quan Sing Ng, Ravindran Kanesvaran, Noan Minh Chau, Min-Han Tan, Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore. Clinical Genitourinary Cancer. ,vol. 13, pp. 285- 295 ,(2015) , 10.1016/J.CLGC.2014.11.004
W.J. Lee, J.L. Lee, S.E. Chang, M.W. Lee, Y.K. Kang, J.H. Choi, K.C. Moon, J.K. Koh, Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib British Journal of Dermatology. ,vol. 161, pp. 1045- 1051 ,(2009) , 10.1111/J.1365-2133.2009.09290.X
N A G Lankheet, J S L Kloth, C G M Gadellaa-van Hooijdonk, G A Cirkel, R H J Mathijssen, M P J K Lolkema, J H M Schellens, E E Voest, S Sleijfer, M J A de Jonge, J B A G Haanen, J H Beijnen, A D R Huitema, N Steeghs, Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours British Journal of Cancer. ,vol. 110, pp. 2441- 2449 ,(2014) , 10.1038/BJC.2014.194
David J. Kwiatkowski, Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biology & Therapy. ,vol. 2, pp. 471- 476 ,(2003) , 10.4161/CBT.2.5.446
Marie-Christine Etienne-Grimaldi, Nicole Renée, Hassan Izzedine, Gérard Milano, A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. Journal of Chromatography B. ,vol. 877, pp. 3757- 3761 ,(2009) , 10.1016/J.JCHROMB.2009.09.011
L Berlin, Standard of care. American Journal of Roentgenology. ,vol. 170, pp. 275- 278 ,(1998) , 10.2214/AJR.170.2.9456928
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026